Perifosine (KRX-0401)

Name: Perifosine (KRX-0401)
Brand: Selleck Chemicals
SKU: S1037
Rating: 5 (150 reviews)

For research use only.

Catalog No.S1037 Synonyms: NSC639966, D21266

150 publications

Perifosine (KRX-0401) Chemical Structure

CAS No. 157716-52-4

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Selleck's Perifosine (KRX-0401) has been cited by 150 publications

Cancer Cell, 2013, 23(6):839-52

PubMed: 23684459 ( click the link to review the publication )

Cell, 2012, 149(3):656-70

PubMed: 22920938 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

IUBMB Life, 2021, 10.1002/iub.2514

PubMed: 34110086 ( click the link to review the publication )

Eur J Pharmacol, 2021, 898:173957

PubMed: 33662352 ( click the link to review the publication )

Aging (Albany NY), 2020, 18;12(10):9489-9499

PubMed: 32421688 ( click the link to review the publication )

Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Toxicol Sci, 2020, kfaa159

PubMed: 33078829 ( click the link to review the publication )

Front Microbiol, 2020, 11:565590

PubMed: 33042070 ( click the link to review the publication )

Cancer Cell Int, 2020, 25;20:134

PubMed: 32351328 ( click the link to review the publication )

J Cell Biochem, 2020, 121(1):723-734

PubMed: 31452248 ( click the link to review the publication )

Transl Oncol, 2020, 13(2):355-364

PubMed: 31887630 ( click the link to review the publication )

Cell Stress Chaperones, 2020, 9

PubMed: 32519137 ( click the link to review the publication )

Chin J Integr Med, 2020, 10.1007

PubMed: 31903532 ( click the link to review the publication )

Commun Biol, 2020, 3(1):378

PubMed: 32665601 ( click the link to review the publication )

Sci Rep, 2020, 10(1):10315

PubMed: 32587277 ( click the link to review the publication )

Biosci Rep, 2020, BSR20201539

PubMed: 33269380 ( click the link to review the publication )

Dev Cell, 2019, 50(2):229-246

PubMed: 31204173 ( click the link to review the publication )

Dev Cell, 2019, 51(2):236-254

PubMed: 31543445 ( click the link to review the publication )

Cancer Lett, 2019, 447:93-104

PubMed: 30660646 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5334

PubMed: 31397884 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31769426 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627436 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(2):356-363

PubMed: 30446585 ( click the link to review the publication )
Cell Prolif, 2019, 52(5):e12638

PubMed: 31152465 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28205

PubMed: 30706473 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31850228 ( click the link to review the publication )

Front Oncol, 2019, 9:422

PubMed: 31192127 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31767884 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 381:114729

PubMed: 31445927 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.28410

PubMed: 30724378 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 511(3):559-565

PubMed: 30824188 ( click the link to review the publication )

Mol Med Rep, 2019, 20(1):33-40

PubMed: 31115502 ( click the link to review the publication )

Med Sci Monit, 2019, 25:7218-7227

PubMed: 31554782 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):911

PubMed: 30185800 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):747

PubMed: 29970878 ( click the link to review the publication )

Cell Death Dis, 2018, 9(7):739

PubMed: 29970892 ( click the link to review the publication )

Front Aging Neurosci, 2018, 10:378

PubMed: 30515090 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

J Cell Biochem, 2018, 119(12):9997-10004

PubMed: 30145830 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(11):1219-1229

PubMed: 30265530 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(8):748-756

PubMed: 29961813 ( click the link to review the publication )

BMC Neurosci, 2018, 19(1):52

PubMed: 30189852 ( click the link to review the publication )

Cell Biol Int, 2018, 42(8):959-964

PubMed: 29569784 ( click the link to review the publication )

Mol Med Rep, 2018, 18(1):447-454

PubMed: 29749519 ( click the link to review the publication )

Transl Cancer Res, 2018, 7(6):1548-1560

PubMed: 30761266 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Oncotarget, 2018, 9(15):12261-12272

PubMed: 29552308 ( click the link to review the publication )
J Pharm Pharmacol, 2018, 70(2):259-267

PubMed: 29148068 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(3):238-251

PubMed: 28218907 ( click the link to review the publication )

Nat Commun, 2017, 8:14091

PubMed: 28345588 ( click the link to review the publication )

Autophagy, 2017, 13(8):1364-1385

PubMed: 28598230 ( click the link to review the publication )

Sci Rep, 2017, 7:45136

PubMed: 28332584 ( click the link to review the publication )

Am J Pathol, 2017, 187(8):1736-1749

PubMed: 28627412 ( click the link to review the publication )

Mediators Inflamm, 2017, 2017:5706152

PubMed: 29056830 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169585

PubMed: 28081222 ( click the link to review the publication )

PLoS One, 2017, 12(3):e0173473

PubMed: 28291820 ( click the link to review the publication )

Med Sci Monit, 2017, 23:5637-5649

PubMed: 29176544 ( click the link to review the publication )

Biotechnol Lett, 2017, 39(9):1343-1349

PubMed: 28597147 ( click the link to review the publication )

Int J Clin Exp Pathol, 2017, 10(9):9400-9408

PubMed: 31966812 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63911-63922

PubMed: 28969040 ( click the link to review the publication )

Sci Rep, 2017, 7:42062

PubMed: 28165023 ( click the link to review the publication )

Oncotarget, 2017, 8(2):2594-2603

PubMed: 27911877 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31666-31681

PubMed: 28427224 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

J Clin Invest, 2016, 126(4):1300-10

PubMed: 26927669 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(6):3130-3145

PubMed: 27980063 ( click the link to review the publication )

Cell Death Dis, 2016, 7:e2043

PubMed: 26775697 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(7):1504-14

PubMed: 27196761 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:305-313

PubMed: 27665476 ( click the link to review the publication )

Exp Cell Res, 2016, 340(1):81-90

PubMed: 26712518 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 479(1):54-60

PubMed: 27614310 ( click the link to review the publication )
Biochem Biophys Res Commun, 2016, 473(4):1170-6

PubMed: 27073162 ( click the link to review the publication )

J Mol Neurosci, 2016, 59(4):567-78

PubMed: 27412469 ( click the link to review the publication )

Anticancer Res, 2016, 36(11):5849-5858

PubMed: 27793908 ( click the link to review the publication )

NPJ Syst Biol Appl, 2016, 2:16027

PubMed: 28725479 ( click the link to review the publication )

Oncotarget, 2016, 7(24):36971-36987

PubMed: 27175591 ( click the link to review the publication )

Tumour Biol, 2016, 37(1):1025-33

PubMed: 26269112 ( click the link to review the publication )

Oncotarget, 2016, 7(16):22687-99

PubMed: 27007150 ( click the link to review the publication )

Biochem Pharmacol, 2015, 10.1016/j.bcp.2015.04.015

PubMed: 25934232 ( click the link to review the publication )

Sci Rep, 2015, 5:12059

PubMed: 26154270 ( click the link to review the publication )

Oncol Rep, 2015, 33(2):875-84

PubMed: 25484022 ( click the link to review the publication )

Mol Cell Biochem, 2015, 398(1-2):105-13

PubMed: 25223639 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: 25269544 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(4):557-62

PubMed: 25712742 ( click the link to review the publication )

Childs Nerv Syst, 2015, 31(2):221-6

PubMed: ( click the link to review the publication )

Tumour Biol, 2015, 10.1007/s13277-015-3244-2

PubMed: 25697899 ( click the link to review the publication )

Oncoscience, 2015,

PubMed: ( click the link to review the publication )

Oncoscience, 2015, 2(4):382-94

PubMed: 26097872 ( click the link to review the publication )

Oncoscience, 2015, 2(4):395-409

PubMed: 26097873 ( click the link to review the publication )

Oncotarget, 2015, 6(9):6597-610

PubMed: 25788264 ( click the link to review the publication )

Oncoscience, 2015, 10.1155/2015/8332

PubMed: ( click the link to review the publication )

Crit Rev Oncol Hematol, 2015,

PubMed: 26253360 ( click the link to review the publication )

Oncotarget, 2015, 6(30):29963-74

PubMed: 26298773 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.184.

PubMed: 24998847 ( click the link to review the publication )
FASEB J, 2014, 27(7):2584-99

PubMed: 23507869 ( click the link to review the publication )

Cardiovasc Diabetol, 2014, 35(7):450-4

PubMed: 24836459 ( click the link to review the publication )

Carcinogenesis, 2014, 35(10):2232-43

PubMed: 24942865 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(9):1851-64

PubMed: 24769208 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02798-13

PubMed: 24752266 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

Pediatr Res, 2014, 75(4):527-34

PubMed: 24366516 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biomed Res Int, 2014, 2014:568693

PubMed: 25309914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 450(1):646-51

PubMed: 24946212 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 453(3):362-7

PubMed: 25264192 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(1):72-8

PubMed: 25152399 ( click the link to review the publication )

Vet J, 2014, 201(1):83-90

PubMed: 24881508 ( click the link to review the publication )

Cell Logist, 2014, 4(1):e27732

PubMed: 24843827 ( click the link to review the publication )

Oncotarget, 2014, 5(14):5295-303

PubMed: 24979463 ( click the link to review the publication )

Rostock University, 2014, Lange F

PubMed: ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Lett, 2013, 336(2):319-24

PubMed: 23528835 ( click the link to review the publication )

Gynecol Oncol, 2013, 131(1):207-12

PubMed: 23877012 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1831(8):1322-34

PubMed: 23707264 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1828(5):1384-9

PubMed: 23376656 ( click the link to review the publication )

Sci Rep, 2013, 3:1697

PubMed: 23603888 ( click the link to review the publication )
J Biol Chem, 2013, 288(31):22836-48

PubMed: 23788636 ( click the link to review the publication )

Mol Pharmacol, 2013, 84(4):562-71

PubMed: 23877009 ( click the link to review the publication )

Biochimie, 2013, 101:50-9

PubMed: 24394624 ( click the link to review the publication )

Oncol Rep, 2013, 29(6):2422-30

PubMed: 23588929 ( click the link to review the publication )

Biochemistry, 2013, 53(3):462-72

PubMed: 24383815 ( click the link to review the publication )

Dig Dis Sci, 2013, 58(10):2873-80

PubMed: 23912246 ( click the link to review the publication )

PLoS One, 2013, 8(5):e61896

PubMed: 23658701 ( click the link to review the publication )

PLoS One, 2013, 8(8): e74420

PubMed: 24009772 ( click the link to review the publication )

PLoS One, 2013, 8(8): e70804

PubMed: 23936469 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 443(2):447-52

PubMed: 24316214 ( click the link to review the publication )

Mol Biol Rep, 2013, 40(10):5645-55

PubMed: 24065522 ( click the link to review the publication )

Mol Med Rep, 2013, 7(2):642-8

PubMed: 23175237 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 65(2):217-27

PubMed: 23015227 ( click the link to review the publication )

Cell Biochem Biophys, 2013, 66(3):737-46

PubMed: 23397419 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(10):2622-33

PubMed: 22461507 ( click the link to review the publication )

J Clin Endocrinol Metab, 2012, 97(2):E173-82

PubMed: 22090271 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(12):1898-912

PubMed: 23001822 ( click the link to review the publication )

J Biol Chem, 2012, 286(43):37389-98

PubMed: 21908616 ( click the link to review the publication )

Expert Opin Inv Drugs, 2012, 21(11):1597-606

PubMed: ( click the link to review the publication )

Mol Carcinog, 2012, 52(9):667-75

PubMed: 22488590 ( click the link to review the publication )

Surgery, 2012, 152(6):1218-24

PubMed: 23158188 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(11):1009-17

PubMed: 22825337 ( click the link to review the publication )

PLoS Biol, 2011, 9(9):e1001148

PubMed: 21931533 ( click the link to review the publication )
Cancer Lett, 2011, 310(1):118-28

PubMed: 21775054 ( click the link to review the publication )

J Pharmacol Exp Ther, 2011, 336(3):866-73

PubMed: 21148684 ( click the link to review the publication )

Radiat Oncol, 2011, 6:39

PubMed: 21496273 ( click the link to review the publication )

Cancer Res, 2010, 70(22):9106-17

PubMed: 21062988 ( click the link to review the publication )

Brit J Pharmacol, 2010, 160(2):355-66

PubMed: 20423345 ( click the link to review the publication )

Cytotechnology, 2010, 62(5):449-60

PubMed: 20842425 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description

Perifosine (KRX-0401, NSC639966, D21266) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Targets

Akt ^[1]
(MM.1S cells)

4.7 μM

In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. ^[1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. ^[2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. ^[3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL-60	MlvnRZBweHSxc3nzJGF{e3OjeR?=	MkDrNVDDqM7:TR?=	NVHSdlk1OjRxNEigbC=>	NGjuNpRqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	M{\vd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
MOLM	NFXj[GJCeG:ydH;zbZMhSXO\|c3H5	M3na[VExyqEQvF2=	MV2yOE81QCCq	NF\iT\|VqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
OCI	MVzBdI9xfG:\|aYOgRZN{e2G7	M{TDdFExyqEQvF2=	NXvLNVN3OjRxNEigbC=>	NF;xR4tqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
BJAB	MlzJRZBweHSxc3nzJGF{e3OjeR?=	MVWxNOKh\|ryP	NFvHN5AzPC92ODDo	MkjQbY5lfWOnczDhdI9xfG:\|aYOgeIlu\S2mZYDlcoRmdnSueR?=	NES2[FM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
MAVER	MYfBdI9xfG:\|aYOgRZN{e2G7	MXGxNOKh\|ryP	MVKyOE81QCCq	NGXPVHJqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
SKW6.4	MXvBdI9xfG:\|aYOgRZN{e2G7	NIjrWVcyOMLizszN	NVrTR3B5OjRxNEigbC=>	NGDWUVNqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5	NIHhfWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
HL-60	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnFcWkzNTFywrFOwG0>	NV7Cd4EzPDkEoHi=	NV;YO3gycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NXjsVXBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|A6PjBpPkKwNVMxQTZyPD;hQi=>
MOLM	NImyZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPOcIYzNTFywrFOwG0>	M3zxeVQ5yqCq	NWDGUZdjcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M1HTb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUOwPVYxLz5{MEGzNFk3ODxxYU6=
OCI	MkXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGyMVExyqEQvF2=	MVm0POKhcA>?	NFPCS\|dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NGDJfJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
BJAB	NITrXZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1P2bVIuOTEEoN88US=>	NGXmSGM1QMLiaB?=	NEfEcGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFzYNYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEGzNFk3OCd-MkCxN\|A6PjB:L3G+
MAVER	M4XFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXO2SW5GOi1zMNMg{txO	MknPOFjDqGh?	MlPrbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF\|MEm2NEc,OjBzM{C5OlA9N2F-
SKW6.4	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PGOlIuOTEEoN88US=>	Ml[1OFjDqGh?	NFTMWm5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MmfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzM{C5OlAoRjJyMUOwPVYxRC:jPh?=
A2780cis	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnXZNE0zOCEQvF2=	Mn;nOFgwPzJiaB?=	NF3sWlNKSzVywrC9xsA3yqEQvH2=	NG\XRpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOVI6Pid-MkC0NFUzQTZ:L3G+
A2780	MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq2RXgxNTJyIN88US=>	NFTvVVE1QC95MjDo	MnztTWM2OMLiPdMgN:Kh\|ryv	NH3mWWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOVI6Pid-MkC0NFUzQTZ:L3G+
SKOV3	NYrac3FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\VOlAuPDBizszN	MXu3NuKhcA>?	M1zrWmlEPTC-M{Cg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mo\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
PA-1	NGXBPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\TNE01OCEQvF2=	MmrOO\|LDqGh?	MW\JR\|UxhjJ3IN88UUwhcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NFn3bZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESwOVI6Pid-MkC0NFUzQTZ:L3G+
OAW-42	M3nLU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojBNE01OCEQvF2=	M2jBd\|czyqCq	Mo\lTWM2OH5zMDFOwG0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MnvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2MEWyPVYoRjJyNEC1Nlk3RC:jPh?=
Bel-7402	NUHUSHFHSXCxcITvd4l{KEG\|c4PhfS=>	MmXkOU8yOC9{MDFOwG0>	NYLrSoh6OjRxNEigbC=>	M2jFOYlv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW=	M4rZOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOESyOFI2Lz5{MEi0NlQzPTxxYU6=
HepG2	M1;scGFxd3C2b4Ppd{BCe3O\|YYm=	MWK1M\|ExNzJyIN88US=>	MWGyOE81QCCq	MmX5bY5lfWOnczDhdI9xfG:\|aYOgZZQhfGinIHzvcocufGmvZTDlfJBwe3W{ZR?=	NF[4ZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi0NlQzPSd-MkC4OFI1OjV:L3G+
Bel-7402	MkDUSpVv[3Srb36gRZN{[Xl?	NUHvbGhQPS9zMD:yNEDPxE1?	MYeyOEBp	NY\LeZpGemW\|dXz0d{BqdiC2aHWgZYNkfW23bHH0bY9vKG:oIHPlcIwhdnWvYnXyJIlvKHSqZTDHNk9OKHCqYYPl	NWnnOXFVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFI1OjVpPkKwPFQzPDJ3PD;hQi=>
HepG2	MmLJSpVv[3Srb36gRZN{[Xl?	NEHUbpo2NzFyL{KwJO69VQ>?	MYeyOEBp	MV;y[ZN2dHS\|IHnuJJRp\SCjY3P1cZVt[XSrb36gc4Yh[2WubDDueY1j\XJiaX6geIhmKEd{L12gdIhie2V?	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh2MkSyOUc,OjB6NEK0NlU9N2F-
Bel-7402	MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPJTll6PS9zMD:yNE81OCEQvF2=	M3LqdlI1NzR6L{eyJIg>	MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MnPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6NEK0NlUoRjJyOESyOFI2RC:jPh?=
HepG2	NHfqXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPnOZVqPS9zMD:yNE81OCEQvF2=	Ml3XNlQwPDhxN{KgbC=>	NXPQU21kcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	NUmxS3pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC4OFI1OjVpPkKwPFQzPDJ3PD;hQi=>
CWR22RV1	NYTDU\|NtTnWwY4Tpc44hSXO\|YYm=	NI[zTHU2KM7:TR?=	NETv[4QzPCCq	NIDkVYdz\WS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBCc3Ric3nncolncWOjboTsfS=>	NEfYflA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS5OlI4Oyd-MkG0PVYzPzN:L3G+
CWR22RV1	MWPBdI9xfG:\|aYOgRZN{e2G7	MkXnNVAh\|ryP	M13H[FI1KGh?	NX7QOI9t\W6qYX7j[ZMhemGmaXH0bY9vKGmwZIXj[YQh[XCxcITvd4l{	NWLFclFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0PVYzPzNpPkKxOFk3Ojd\|PD;hQi=>
CWR22RV1	NFW4fmVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MkX6NVAh\|ryP	MlfPNlQhcA>?	NUezd4d2cW6lcnXhd4V{KHOnboPpeIl3cXS7IH;mJIh2dWGwIFPXVlIzWlZzIHPlcIx{KHSxIILh[IlifGmxbh?=	MkLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2OU[yO\|MoRjJzNEm2Nlc{RC:jPh?=
A498	M{LLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKwMVIxKM7:TR?=	MnHpO\|IhcA>?	NGLFVGNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NHLzRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
769-P	NV;ZXppwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnT2NE0zOCEQvF2=	M4PMTlczKGh?	M1\VTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NV[5cId3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
CAKI-1	M{W2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXHUFQ3OC1{MDFOwG0>	NH31SlE4OiCq	NH\RZpVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NESwOVAoRjJzNkS0NFUxRC:jPh?=
786-O	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LkelAuOjBizszN	NVPNeIdvPzJiaB?=	MVjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NEnLUJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
786-0	M{j6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUTDdZpnOC12MDFOwG0>	MmjnO\|IhcA>?	MYfJR\|UxhjVizszN	NUnXN5ZFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2OFQxPTBpPkKxOlQ1ODVyPD;hQi=>
769-P	NFjNN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWewMVQxKM7:TR?=	NHzYZWU4OiCq	NILaeXNKSzVyfkWtNVAh\|ryP	MmfsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4NESwOVAoRjJzNkS0NFUxRC:jPh?=
CAKI-1	NGjuW3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17RdFAuPDBizszN	NG[xSWg4OiCq	MnrwTWM2OH5zMDFOwG0>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ2NEC1NEc,OjF4NESwOVA9N2F-
A498	MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3BcY9ROC12MDFOwG0>	MkPIO\|IhcA>?	M1\Dc4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NECwco89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[0OFA2OCd-MkG2OFQxPTB:L3G+
HT-29	M1fsUWN6fG:2b4jpZ4l1gSCDc4PhfS=>	NH74TWU2KM7:TR?=	MYq0PEBp	MX\lcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	NHjVSm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3OVA2PCd-MkG3O\|UxPTR:L3G+
A2780	NWHCVpVNS3m2b4TvfIlkcXS7IFHzd4F6	MYO1JO69VQ>?	NVjIeYpPPDhiaB?=	NH7xT\|hmdmijbnPld{Bx[WOuaYThfIVtKGmwZIXj[YQhd3[jcnnhckBk[W6lZYKgZ4VtdCCmZXH0bOKh	M1vodFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{e1NFU1Lz5{MUe3OVA2PDxxYU6=
SKOV3	NYrVclJxS3m2b4TvfIlkcXS7IFHzd4F6	MmP6OUDPxE1?	M3S5WlQ5KGh?	MWnlcohidmOnczDwZYNtcXSjeHXsJIlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	NFfKUGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3OVA2PCd-MkG3O\|UxPTR:L3G+
CaOV3	NH7JOG5E\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NVjnV3FJOS93L{GwJO69VQ>?	MUi0PEBp	M2KyOYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6ncjDjc5Rz\WG2ZXSge4l1cCCyYXPsbZRigGWu	MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{WwOVQoRjJzN{e1NFU1RC:jPh?=
OCUT1	Mme4SpVv[3Srb36gRZN{[Xl?	MYWzJO69dQ>?	NVnCTlBiOjRiaB?=	NGjXdJVk[XW\|ZYOgZUBlemGvYYTpZ{BqdmO{ZXHz[UBqdiCJMj;NJJBp[XOn	M3HW[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEmwNlcyLz5{MkC5NFI4OTxxYU6=
K1	NGXZTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrORmNoOC5zLUOg{txO	MoHBOUBl	M2XQPYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NFr0TFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC5NFI4OSd-MkKwPVAzPzF:L3G+
OCUT1	NYH0UGlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[wMlEuOyEQvF2=	NYXHO4xsPSCm	NXfodYVTcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB7MEK3NUc,OjJyOUCyO\|E9N2F-
K562	MoiwSpVv[3Srb36gRZN{[Xl?	Mn3nNlAh\|ryP	M4jOd\|Q5KGh?	NVHxZ\|JIcW6mdXPld{BifXSxcHjh[5nDqA>?	NX3Ue5ZjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFczOjhpPkKyOFA4OjJ6PD;hQi=>
HL-60	NHLrdVNHfW6ldHnvckBCe3OjeR?=	NH22U4IzNjVxNT:xNEDPxE1?	MnL0NlQhcA>?	MXLpcoR2[2W\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MkOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MEeyNlgoRjJ{NEC3NlI5RC:jPh?=
Kasumi-1	MYLGeY5kfGmxbjDBd5NigQ>?	MkHKNk42NzVxMUCg{txO	M2DoNlI1KGh?	MUnpcoR2[2W\|IITo[UBxcG:\|cHjvdplt[XSrb36gc4YhUk6NMT:yJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MEeyNlgoRjJ{NEC3NlI5RC:jPh?=
HL-60	NV7t[2Z2TnWwY4Tpc44hSXO\|YYm=	NW\kR3F6Oi53L{WvNVAh\|ryP	MXOyOEBp	NGDXVIll\WO{ZXHz[ZMhSWu2IHHu[EBxNUGtdDDs[ZZmdHQEoHTvd4Uu\GWyZX7k[Y51dHl?	M{XFVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC3NlI5Lz5{MkSwO\|IzQDxxYU6=
Kasumi-1	NFfaWmNHfW6ldHnvckBCe3OjeR?=	Mof5Nk42NzVxMUCg{txO	MkXyNlQhcA>?	M4XpeYRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
HL-60	M2TXcmFxd3C2b4Ppd{BCe3O\|YYm=	NWHjdpZ{OTBizszN	MmLhNlQhcA>?	NWj3NXVvcW6mdXPld{BieG:ydH;zbZM>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRyN{KyPEc,OjJ2MEeyNlg9N2F-
Kasumi-1	MVXBdI9xfG:\|aYOgRZN{e2G7	MWWxNEDPxE1?	MkSzNlQhcA>?	NYX0bVdncW6mdXPld{BieG:ydH;zbZM>	MofvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2MEeyNlgoRjJ{NEC3NlI5RC:jPh?=
HL-60	M2nU[2NmdGxiVnnhZoltcXS7IFHzd4F6	MWewMVIxKM7:TR?=	MV:yOE81QCCq	M1PvNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	NVu2VnBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NFczOjhpPkKyOFA4OjJ6PD;hQi=>
Kasumi-1	MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MkjGNE0zOCEQvF2=	MmfvNlQwPDhiaB?=	M3PZXoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	M{PvPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NEC3NlI5Lz5{MkSwO\|IzQDxxYU6=
BON1	MWLGeY5kfGmxbjDBd5NigQ>?	NF;3RoU4NjVxMUCg{txO	NX3DRVRYQCCq	Mkji[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJRp\SCjboTpMYFxd3C2b4TpZ{Bxem:2ZXnud{BDS0x{IHHu[EBD[2xvWFy=	Mkj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ2OUm0N\|coRjJ{NEm5OFM4RC:jPh?=
BON1	NXnJZ5MySXCxcITvd4l{KEG\|c4PhfS=>	M1yweFAuOTBizszN	NV3xPGRKOjRiaB?=	MX3pcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NVXjUlhqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVk1OzdpPkKyOFk6PDN5PD;hQi=>
BON1	MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NVLLT5RsOC1zMECg{txO	NW\tWYJmOjRxN{KgbC=>	MVTk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NY\aVHIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVk1OzdpPkKyOFk6PDN5PD;hQi=>
GOT1	NVmzSmQ{S2WubDDWbYFjcWyrdImgRZN{[Xl?	MWSwMVExOCEQvF2=	MWCyOE84OiCq	MVnk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NWC4eJpjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0PVk1OzdpPkKyOFk6PDN5PD;hQi=>
NCI-H727	M{DGSGNmdGxiVnnhZoltcXS7IFHzd4F6	NYjBVm4yOC1zMECg{txO	M4LOUVI1Nzd{IHi=	M2PkUoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjR7OUSzO{c,OjJ2OUm0N\|c9N2F-
MCAS	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M173N2lEPTB;MUKuOUDPxE1?	NXj0bpA2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
A2780S	NEjzXWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3rlcWlEPTB;MUSuOUDPxE1?	NF[1enk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
OVCAR5	MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHz6[XRKSzVyPU[uO{DPxE1?	MoDMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
A2780CP	Mki0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{\KeWlEPTB;Nz62JO69VQ>?	NH\zNmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
HeyA8	NIrHe41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkjETWM2OD1{ND6zJO69VQ>?	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
OVCAR8	MlPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIribohKSzVyPUOxMlEh\|ryP	MmTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6N{ewNVIoRjJ\|OEe3NFEzRC:jPh?=
M41R	NXvY[2hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUn2PFk6UUN3ME2xPU45KM7:TR?=	NYfnT\|U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4O\|cxOTJpPkKzPFc4ODF{PD;hQi=>
M41	NX7M[IJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2XGVGlEPTB;MkSuO{DPxE1?	NEDld2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
TykNuR	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXTxV2FKUUN3ME21MlUh\|ryP	NGPj[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i3O\|AyOid-MkO4O\|cxOTJ:L3G+
TykNu	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGjJSFFKSzVyPUOuOUDPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh5N{CxNkc,OjN6N{ewNVI9N2F-
MGC803	NXTCT5lUTnWwY4Tpc44hSXO\|YYm=	MX2wMlc2NzFywrFOwG0>	MUK0POKhcA>?	NY\Xc5ZH\GWlcnXhd4V{KHBvQXv0JEhU\XJiNEezLUwheC2JU1uz{tIhMFOncjC5LUwh[W6mIFOtUXlEKGyndnXsd:Kh	NVm3bWVZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVIzPDZpPkKzPVEzOjR4PD;hQi=>
SGC7901	MWnGeY5kfGmxbjDBd5NigQ>?	NWjkNJRWOC55NT:xNOKh\|ryP	MlnmOFghcA>?	M3X2OoRm[3KnYYPld{BxNUGtdDCoV4VzKDR5MzmsJJAuT1ONM98yJEhU\XJiOTmsJIFv\CCFLV3ZR{Bt\X[nbIRCpC=>	M3rub\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUGyNlQ3Lz5{M{mxNlI1PjxxYU6=
U87MG	MlLWR4VtdCCYaXHibYxqfHliQYPzZZk>	MnPyNE0zPSEQvF2=	MYmyOE06PiCq	MnLo[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	MnrRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNkW1NlIoRjJ2ME[1OVIzRC:jPh?=
AsPC-1	M1PJfGZ2dmO2aX;uJGF{e2G7	NHPiW5kxNjVizszN	M4PWfVI1KGh?	M3X3TIlvcGmkaYTzJGFsfCxiU{\LNUwh[W6mIFXyb\|EwOiCyaH;zdIhwenmuYYTpc47DqA>?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDVzOUe1NUc,OjR3MUm3OVE9N2F-
MIA	NHTT[ZlHfW6ldHnvckBCe3OjeR?=	MUOwMlUh\|ryP	MofPNlQhcA>?	NIDjNVJqdmirYnn0d{BCc3RuIGO2T\|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB?	M4HKRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUG5O\|UyLz5{NEWxPVc2OTxxYU6=
PANC-1	MY\GeY5kfGmxbjDBd5NigQ>?	MoTLNE42KM7:TR?=	M3XlPFI1KGh?	NHrKfHpqdmirYnn0d{BCc3RuIGO2T\|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB?	NX7DcZFPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NVk4PTFpPkK0OVE6PzVzPD;hQi=>
AsPC-1	M3:1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXiwMVI2KM7:TR?=	NX\wRpVSPzJiaB?=	NXu1XnBYcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NHHrTYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWxPVc2OSd-MkS1NVk4PTF:L3G+
MIA	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUewMVI2KM7:TR?=	MWq3NkBp	MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	M2f0U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUG5O\|UyLz5{NEWxPVc2OTxxYU6=
PANC-1	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jDRVAuOjVizszN	MUe3NkBp	Mke2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI>	NEWzVms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWxPVc2OSd-MkS1NVk4PTF:L3G+
Ema	NIrmcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV2wMlHjiJNzMEFihKnPxE1?	MkjKOFghcA>?	MVvJR\|UxRTV6Lkeg{txO	NHTnTnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4NVUxQCd-MkS4PFE2ODh:L3G+
UL-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUiwMlHjiJNzMEFihKnPxE1?	MojROFghcA>?	MojDTWM2OD15LkCxJO69VQ>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6MUWwPEc,OjR6OEG1NFg9N2F-
CLBL-1	NWG1PWRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHwb3IxNjIkgKOxNFDjiIoQvF2=	NHjEXWs1QCCq	M17aWGlEPTB;M{OuNEDPxE1?	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OEG1NFgoRjJ2OEixOVA5RC:jPh?=
GL-1	M1y0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIXlU3ExNjIkgKOxNFDjiIoQvF2=	M2HJNVQ5KGh?	M4LUZWlEPTB;OT65NUDPxE1?	NUiwOlBLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PFE2ODhpPkK0PFgyPTB6PD;hQi=>
MDA-MB-231	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnwUVNbOC1zMDFOwG0>	MYC0PEBp	MUTFR\|UxRTFwMURihKnDueLCiUCuNFch\|ryP	NFnYNFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5N\|U4Pid-MkWyPVM2PzZ:L3G+
HCC1806	M{XOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX[wMVExKM7:TR?=	NYn0UYNZPDhiaB?=	M4LhSWVEPTB;Mj64OQKBkcLz4pEJNE4xPyEQvF2=	M1HVT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkmzOVc3Lz5{NUK5N\|U4PjxxYU6=
RMG2	MnHpRZBweHSxc3nzJGF{e3OjeR?=	M3TpclMxKM7:TR?=	NV7WTms2OjRiaB?=	NF:1SpNqdmS3Y3XzJIFxd3C2b4Ppdy=>	NYPiNIlbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
RMG1	NXryOmRQSXCxcITvd4l{KEG\|c4PhfS=>	MUKzNEDPxE1?	M4\YUlI1KGh?	MXvpcoR2[2W\|IHHwc5B1d3Orcx?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
A2780	Ml3FR4VtdCCYaXHibYxqfHliQYPzZZk>	M4HIZ\|EuOzBizszN	NYjBOJFPPDhiaB?=	MXfk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWnPfVJvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
SKOV3	NISxVJNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NXXJeZBwOS1\|MDFOwG0>	MVG0PEBp	Mn6z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
OVISE	M2LWS2NmdGxiVnnhZoltcXS7IFHzd4F6	MkTDNU0{OCEQvF2=	NF3VfpU1QCCq	M{[1UYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
RMG2	M135RmNmdGxiVnnhZoltcXS7IFHzd4F6	M3y3T\|EuOzBizszN	NYLKOHhGPDhiaB?=	NV7PWZZw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NGLPflc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUWxPVE1QCd-MkW1NVkyPDh:L3G+
HAC2	NUO0W4dyS2WubDDWbYFjcWyrdImgRZN{[Xl?	NUfjem9jOS1\|MDFOwG0>	M{LmTlczKGh?	NGHKc\|Rl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M2LnRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
KOC7C	NFfITpZE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MWKxMVMxKM7:TR?=	NHixSlc4OiCq	M2L5NIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M3rSVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUG5NVQ5Lz5{NUWxPVE1QDxxYU6=
RMG2	Mne4R4VtdCCYaXHibYxqfHliQYPzZZk>	MnO3NU0{OCEQvF2=	MV[3NkBp	NV\u[GxV\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTVzOUG0PEc,OjV3MUmxOFg9N2F-
RMG1	MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1HRWlEuOzBizszN	MkXNO\|IhcA>?	MlXz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NX\mZ5Q2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW1NVkyPDhpPkK1OVE6OTR6PD;hQi=>
H460	M{LlNWZ2dmO2aX;uJGF{e2G7	NXvRRYVXOyEQvF2=	MXe4JIg>	NUXyOXl3[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y	NXfZXXJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
A549	MYXGeY5kfGmxbjDBd5NigQ>?	NWTjXWhbOyEQvF2=	MkDTPEBp	Ml70Zoxw[2u\|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{	Mmm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUe4PVkoRjJ3Nkm3PFk6RC:jPh?=
H460	NXPjTZJlTnWwY4Tpc44hSXO\|YYm=	MkexN{DPxE1?	NEXtdmI5KGh?	NUnzbHNI[myxY3vzJGFMXCCjY4TpeoF1cW:w	M2nVOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
A549	MnfFSpVv[3Srb36gRZN{[Xl?	MlfsN{DPxE1?	NWX2R3BkQCCq	NYXaUnp2[myxY3vzJGFMXCCjY4TpeoF1cW:w	MkDpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OUe4PVkoRjJ3Nkm3PFk6RC:jPh?=
H460	NHTiS2JCeG:ydH;zbZMhSXO\|c3H5	MlHvNU8{KM7:TR?=	NH\Qcpg1QCCq	MWHpcoR2[2W\|IHHwc5B1d3Orcx?=	M2D3bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
A549	M4L0cWFxd3C2b4Ppd{BCe3O\|YYm=	NX2weI9kOS9\|IN88US=>	NXjPcoFQPDhiaB?=	MoDJbY5lfWOnczDhdI9xfG:\|aYO=	NU[yfnNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PVc5QTlpPkK1Olk4QDl7PD;hQi=>
H460	M2nV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml:yNE4{NTFyIN88US=>	NV\PRphCOjRxN{KgbC=>	MkPabY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	M33V[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
A549	NYHudHRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\NZXcxNjNvMUCg{txO	M4f5R\|I1Nzd{IHi=	NIrRSYZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M4frNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nkm3PFk6Lz5{NU[5O\|g6QTxxYU6=
U-87 MG	M2DnNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVWyNE81OCEQvF2=	NFzqUGozPC92ODDo	M1S2c4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NVuwbHBMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5N\|QzOzJpPkK1PVM1OjN{PD;hQi=>
HepG2	NHnjUJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTGN2RoOjBxNECg{txO	NUXXPXRLOjRxNEigbC=>	NXrvT2p{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	M{\kUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlMzLz5{NUmzOFI{OjxxYU6=
U-87 MG	MVnGeY5kfGmxbjDBd5NigQ>?	NIPS[FEzOMLizszN	MnX6Ok8zPCCq	M12zeolv[3KnYYPld{B1cGViYYX0c5Bp[WerYzDmcJV5KCCjdDC2JIghf2irbHWgbY5pcWKrdIOgeIhqeyCobIX4JIF1KDJ2aB?=	M{C1U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlMzLz5{NUmzOFI{OjxxYU6=
HepG2	NGnqR5NHfW6ldHnvckBCe3OjeR?=	MofmNlDDqM7:TR?=	NY\H[2h5Pi9{NDDo	NX3qOYhX\GWlcnXhd4V{KEyFMz3JTUBl\We{YXTheIlwdsLiZoLvcUA3KGh?	M3fy[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUO0NlMzLz5{NUmzOFI{OjxxYU6=
U-87 MG	NGLNeVZHfW6ldHnvckBCe3OjeR?=	NWTDfXpnOjEEoN88US=>	NIqzeYc3NzJ2IHi=	MknLbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS	NEfEPYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzOFI{Oid-MkW5N\|QzOzJ:L3G+
HepG2	MnrLSpVv[3Srb36gRZN{[Xl?	MXuyNOKh\|ryP	NIDlR4s3NzJ2IHi=	M1;XbYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
U-87 MG	NWL0U2k2TnWwY4Tpc44hSXO\|YYm=	NE\yeWozOMLizszN	NIP3N4gzPMLiaB?=	NVLPbW56cW6lcnXhd4V{KGSxdXLs[U1u\W2kcnHu[UBjd3WwZDDzeJJ2[3S3cnXz	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl\|NEKzNkc,OjV7M{SyN\|I9N2F-
HepG2	MWjGeY5kfGmxbjDBd5NigQ>?	M4eyWFIxyqEQvF2=	Mm[4NlTDqGh?	MlXQdJJw\HWlZYOgZY4hcW62ZX7z[UBkgXSxcHzhd41q[yC4YXP1c4xqgmG2aX;uJINwenKnc4DvcoRqdmdidH:gZUBvd3SjYnzlJIRqdGG2YYTpc44hd2ZidHjlJGVTKGOrc4Tldo5{	NETld5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmzOFI{Oid-MkW5N\|QzOzJ:L3G+
T24 BC	NHjDSlJCeG:ydH;zbZMhSXO\|c3H5	MXyyMlUh\|ryP	NVn4PHlLOjRiaB?=	M2rBVJNmdnOrdHn6[ZMhSkNiY3XscJMhfG9ic3;yZYZmdmmkLXnu[JVk\WRiYYDvdJRwfGmlwrC=	NU\OSYN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPVc5PzNpPkK2NFk4QDd\|PD;hQi=>
T24 BC	M1ztVmNmdGxiVnnhZoltcXS7IFHzd4F6	NWDMNGRFOC53L{GvNk42KM7:TR?=	MV[yOEBp	MWXlcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>?	M1Lh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEm3PFc{Lz5{NkC5O\|g4OzxxYU6=
T24 BC	NWXhTGR5TnWwY4Tpc44hSXO\|YYm=	MVywMlUwOS9{LkWg{txO	MoLBN{Bp	MV;y[YR2[2W\|IITo[UBj[XOjbDDDRkB1gXKxc3nu[UBxcG:\|cHjvdplt[XSrb36gcIV3\Wy\|IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB7N{i3N{c,OjZyOUe4O\|M9N2F-
RBL2H3	Mm\tSpVv[3Srb36gZZN{[Xl?			M2PMW3RwgGmlaYT5JIlvKHKjdDDSRmwzUDNiY3XscJMtKE2WRE2yOe69VQ>?	NEjZelc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1N\|U3PSd-MkCxOVM2PjV:L3G+
PC3	Mn\SS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NGDaVpVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBRSzNiY3XscJMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhT0l3ME2wMlQ1\|ryP	MlLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
NUGC3	MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MWnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOWWdEOyClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUCuOVTPxE1?	NHPZTYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW0N\|E1OSd-MkG1OFMyPDF:L3G+
HCT15	M4DXNmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NGnSboRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJS1RzNTDj[YxteyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwQVEvOjYQvF2=	M3nhb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNUSzNVQyLz5{MUW0N\|E1OTxxYU6=
MDA-MB-231	NHf1TItIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MnrJS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxRTJwOEdOwG0>	Mn;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NEOxOFEoRjJzNUSzNVQyRC:jPh?=
NCI-H23	NEDGe2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MX7Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUC9OE4zOc7:TR?=	NXfs[3RXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1OFMyPDFpPkKxOVQ{OTRzPD;hQi=>
ACHN	Ml20S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			MmXkS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRWNJViClZXzsd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUSuOVbPxE1?	NWGze4ZZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1OFMyPDFpPkKxOVQ{OTRzPD;hQi=>
A549	MVrGeY5kfGmxbjDhd5NigQ>?		MlnGN\|AhdWmwcx?=	MlLyTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIlve3WuaX6td5RqdXWuYYTl[EBpfW2jbjDBOVQ6KGOnbHzzJJRz\WG2ZXSgNkBpenNiYnXmc5JmKGmwc4XsbY4he3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOzBibXnud{BjgSCHTFnTRUwhUUN3ME21MlPPxE1?	M{WwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO4N\|A6Lz5{MkGzPFMxQTxxYU6=
A549	MULDfZRwfG:6aXPpeJkh[XO\|YYm=		NYT5SmM1OjRiaILz	M3q1cGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVA:P87:TR?=	M1fBOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO4N\|A6Lz5{MkGzPFMxQTxxYU6=
KATO III	NVz4[VB2S3m2b4TvfIlkcXS7IHHzd4F6		M1G2flI1KGi{cx?=	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRXRQKEmLSTDj[YxteyCjZoTldkAzPCCqcoOgZpkhTkGFUzDhcoFtgXOrczygTWM2OD1zMj64{txO	M4W5N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUO4N\|A6Lz5{MkGzPFMxQTxxYU6=
MCF7	NXrzNo5nS3m2b4TvfIlkcXS7IHHzd4F6		MnnyNlQhcHK\|	M1fF[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVA:OTNwM988US=>	NIL1bJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGzPFMxQSd-MkKxN\|g{ODl:L3G+
PC3	NFX5SINIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NGXtNnBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBRSzNiY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTBwNEVOwG0>	NWTTR4QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlYyQDFpPkKzNlY3OThzPD;hQi=>
NUGC3	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MVrHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOWWdEOyClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:OC53NN88US=>	NXXXNmM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlYyQDFpPkKzNlY3OThzPD;hQi=>
HCT15	M1PIZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			M3fCbWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDF3IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD1zLkK1{txO	NVv1cll{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOyOlYyQDFpPkKzNlY3OThzPD;hQi=>
MDA-MB-231	Mn7yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			NH[0dotIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjh4zszN	MmjtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[xPFEoRjJ\|Mk[2NVgyRC:jPh?=
NCI-H23	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			MYPHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkKx{txO	M4[zXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|Mk[2NVgyLz5{M{K2OlE5OTxxYU6=
ACHN	NG\ucHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NIj3UmRIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCS0iQIHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkW2{txO	MkHGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nk[xPFEoRjJ\|Mk[2NVgyRC:jPh?=
A549	M1TGZ2Z2dmO2aX;uJIF{e2G7		M3;TWVIhcHK\|	MYPJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iaX7zeYxqdi2\|dHnteYxifGWmIFG1OFkh[2WubIOgbY5kfWKjdHXkJIZweiB{IHjyd{BxemmxcjD0c{BqdnO3bHnuMYlv\HWldHnvckBu\WG\|dYLl[EBi\nSncjCzNEBucW6\|IHL5JGVNUVODLDDJR\|UxRTVwM988US=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzNUC4N{c,OjN2MUWwPFM9N2F-
A549	NV3WRo9WS3m2b4TvfIlkcXS7IHHzd4F6			MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIJ6KG[ub4egZ5l1d22ndILpZ{BidmGueYPpd{whUUN3ME23{txO	NEmyWYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{SxOVA5Oyd-MkO0NVUxQDN:L3G+
KATO III	Moe3R5l1d3SxeHnjbZR6KGG\|c3H5			NIT0U5ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSVSRIFnJTUBk\WyuczDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm\|aYOsJGlEPTB;MUKuPO69VQ>?	NX3uO2pJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NVUxQDNpPkKzOFE2ODh\|PD;hQi=>
MCF7	MWrDfZRwfG:6aXPpeJkh[XO\|YYm=			M1zRXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVE{NjQQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzNUC4N{c,OjN2MUWwPFM9N2F-
PC3	MnTZRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MnviRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUCuOFTPxE1?	NFX3S5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k2OCd-MkO1Olc6PTB:L3G+
NUGC3	NFLiVndCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MnW1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQVVfDN{Bk\WyuczDifUBUWkJiYYPzZZktKEeLNUC9NE42PM7:TR?=	M3SxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVUxLz5{M{W2O\|k2ODxxYU6=
HCT15	NYG4bZZrSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NF7ZTGdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIJ6KFOUQjDhd5NigSxiR1m1NF0yNjJ3zszN	Ml\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3Nke5OVAoRjJ\|NU[3PVUxRC:jPh?=
MDA-MB-231	NF\BXIpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NHHxfJlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHNiYomgV3JDKGG\|c3H5MEBIUTVyPUKuPFbPxE1?	M3nUOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVUxLz5{M{W2O\|k2ODxxYU6=
NCI-H23	NHvRfVlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NXrIelZLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGK7IGPSRkBie3OjeTygS2k2OD12LkKx{txO	NH\JO4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W2O\|k2OCd-MkO1Olc6PTB:L3G+
ACHN	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NFLlPFJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFHDTG4h[2WubIOgZpkhW1KEIHHzd4F6NCCJSUWwQVQvPTcQvF2=	M4OxcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NU[3PVUxLz5{M{W2O\|k2ODxxYU6=
PC3	NWDyTlVvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFO4[nc1QCCqcoO=	NUiyU3JQT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hWEN\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9NE41PM7:TR?=	NXGwUnJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
NUGC3	MmLKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MX60PEBpenN?	Mn;aS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUnVISzNiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3ME2wMlU1\|ryP	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB7NUe1PUc,OjRyOUW3OVk9N2F-
HCT15	NU\IXVR5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml3HOFghcHK\|	MlrnS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTViY3XscJMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhT0l3ME2xMlI2\|ryP	MojVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyOUW3OVkoRjJ2MEm1O\|U6RC:jPh?=
MDA-MB-231	NVnmfIdVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFzWfG81QCCqcoO=	NYKyZ\|V6T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bi\nSncjC0PEBpenNiYomgV3JDKGG\|c3H5MEBIUTVyPUKuPFbPxE1?	NWfwUW5NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
NCI-H23	NH74dJJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGmybXg1QCCqcoO=	MUDHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDOR2kuUDJ\|IHPlcIx{KGGodHXyJFQ5KGi{czDifUBUWkJiYYPzZZktKEeLNUC9OE4zOc7:TR?=	NEi2b3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC5OVc2QSd-MkSwPVU4PTl:L3G+
ACHN	NU[x[VU3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4P5S\|Q5KGi{cx?=	MW\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBR2hPKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDTVmIh[XO\|YYmsJGdKPTB;ND61Ou69VQ>?	NV3kUWdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwPVU4PTlpPkK0NFk2PzV7PD;hQi=>
A549	M3u2fWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MX[yOEB1dyB5MjDodpM>	NXSyc4hmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkAzPCC2bzC3NkBpenNiYomgbIFmdW:leYTvcYV1enluIFnDOVA:PC5zN988US=>	NYTXeZlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3OjBpPkK0PVAxPjJyPD;hQi=>
Rosetta cells	NGXKeXpHfW6ldHnvckBie3OjeR?=			MWTJcohq[mm2aX;uJI9nKHerbHSteJlx\SCqdX3hckBROzijbIDoZUBOSVCNIHX4dJJme3OnZDDpckBGe2OqZYLpZ4hq[SClb3zpJHJwe2W2dHGgZ4VtdHNuIFnDOVA:OS5{zszN	MmTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzF{N{SzNVYoRjNzMke0N\|E3RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-S6K1 / S6K1 ; PubMed: 25519148 Mol Cancer Res The effect of perifosine on AKT-mTOR activation in vitro. RMG1 and RMG2 cells were treated with 0, 3, 10, 30 or 50 μM perifosine for 6 h in the presence of 10% FBS. Cells were harvested, and equivalent amounts (30 μg) of protein were subjected to SDS-PAGE and blotted with anti-phospho-AKT (Ser473), anti-AKT, anti-phospho-S6K1 (Thr389), anti-S6K1, or anti-β-actin antibodies. PARP; PubMed: 25519148 Mol Cancer Res Perifosine induces apoptosis. RMG1 and RMG2 cells were treated with or without 30 μM perifosine for 24 h. Cells were harvested, and the effect of perifosine was evaluated by western blotting p-mTOR / mTOR / Raptor / Rictor / p-p70S6K / p70S6K / p-4EBP1 / 4EBP1 / c-Myc / Cyclin D1; PubMed: 19920197 Cancer Res The indicated cell lines were treated with the given concentrations of perifosine (PRFS) for 8 h. p-PDK1 / p-GSK3α/β / p-S6R ; PubMed: 17761832 Blood BCWM.1 cells were cultured with perifosine for 6 hours with doses that ranged from 2 to 20 μM. Whole cell lysates were subjecting to Western blotting using anti–p-Akt ser473, -Akt, –p-PDK1, –p-GSK3α/β, –p-S6R, and α-tubulin antibodies.	25519148 19920197 17761832
Growth inhibition assay	Cell viability; PubMed: 28332584 Sci Rep Cell survival measured by MTT assay and IC50 of perifosine in a panel of eleven human cancer cells.	28332584

In vivo

Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. ^[2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. ^[3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. ^[5]

Protocol

Kinase Assay:^[3]	- Collapse Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:^[2]	- Collapse Cell lines: Human glioma cell lines Concentrations: 0, 15, 30 and 45 μM Incubation Time: 48 hours Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader. (Only for Reference)
Animal Research:^[3]	- Collapse Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old). Dosages: 250 mg/kg/wk or 36 mg/kg/d Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	8 mg/mL (17.32 mM)
	DMSO	Insoluble
	Ethanol	'15 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Perifosine (KRX-0401) SDF

Molecular Weight	461.66
Formula	C₂₅H₅₂NO₄P
CAS No.	157716-52-4
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NSC639966, D21266
Smiles	CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](CC1)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01224730	Completed	Drug: perifosine	Cancer	AEterna Zentaris	January 24 2012	Phase 1
NCT01048580	Completed	Drug: Perifosine\|Drug: Capecitabine	Colon Cancer	AEterna Zentaris\|SCRI Development Innovations LLC	October 2009	Phase 1
NCT00498966	Completed	Drug: Perifosine	Kidney Cancer	AEterna Zentaris	July 2007	Phase 2
NCT00448721	Completed	Drug: Perifosine	Renal Cell Carcinoma	AEterna Zentaris\|Dana-Farber Cancer Institute	March 2007	Phase 2
NCT00455559	Completed	Drug: Perifosine\|Drug: Imatinib Mesylate	Gastrointestinal Stromal Tumors	AEterna Zentaris\|M.D. Anderson Cancer Center	August 2006	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Selective Akt Inhibitor

CCT128930 : AKT2-selective, IC50=6 nM.
Most Potent Akt Inhibitor

AZD5363 : Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.
Akt Inhibitor in Clinical Trial

Ipatasertib (GDC-0068) : Phase II for Prostate Cancer and Gastric Cancer.
Newest Akt Inhibitor

AZD5363 : Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Related Akt Products

Afuresertib (GSK2110183) ^New

Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with K_i of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.
AT13148 ^New

AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.
SC79 ^New

SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
Capivasertib (AZD5363)

Capivasertib (AZD5363) potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Ipatasertib (GDC-0068)

Ipatasertib (GDC-0068, RG7440) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.
GSK690693

GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. GSK690693 also potently inhibits AMPK and DAPK3 from the CAMK family with IC50 of 50 nM and 81 nM, respectively. GSK690693 affects Unc-51-like autophagy activating kinase 1 (ULK1) activity, robustly inhibits STING-dependent IRF3 activation. Phase 1.
Triciribine (NSC 154020)

Triciribine (NSC 154020, VD-0002, vqd-002, API-2, TCN) is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lacking adenosine kinase. Phase 1/2.
Honokiol (NSC 293100)

Honokiol (NSC 293100) is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. Honokiol causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. Honokiol inhibits hepatitis C virus (HCV) infection. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Perifosine (KRX-0401)